What are Veradermics 's total assets?

Veradermics (MANE) holds $397.4M in total assets.

How much cash does Veradermics have?

Veradermics holds $168.4M in cash and equivalents.

Can Veradermics cover its short-term obligations?

Its current ratio is 59.12 — current assets exceed current liabilities.

Where does Veradermics 's balance sheet data come from?

Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Veradermics MANE Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q1 '25	Q4 '24	Q3 '24
Cash and cash equivalents	$168.41M+674%	$21.77M-32.9%	$32.44M-38.9%	$53.08M—	——
Short-term investments	$222.39M+85.2%	$120.1M—	——	$0—	——
Prepaid expenses and other current assets	$6.27M-41.0%	$10.63M+13,558%	-$79K-103%	$2.45M+727%	$296.25K0.0%
Total current assets	$397.07M+160%	$152.49M—	——	$55.54M—	——
Property and equipment, net	$21K-4.5%	$22K—	——	$0—	——
Operating lease right-of-use assets	——	$103K—	——	$0—	——
Total noncurrent assets	$287K+130%	$125K—	——	$0—	——
Total assets	$397.36M+160%	$152.62M—	——	$55.54M—	——
Accounts payable	$1.07M-49.6%	$2.13M+410%	-$686K-131%	$2.25M+1,292%	$161.5K0.0%
Accrued expenses	——	$47K—	——	$0—	——
Total current liabilities	$6.72M-26.6%	$9.15M—	——	$4.72M—	——
Operating lease liabilities, non-current	$0-100%	$4K—	——	$0—	——
Total liabilities	$6.72M-26.6%	$9.16M—	——	$4.72M—	——
Common stock	——	$1K—	——	$1K—	——
Additional paid-in capital	$543.04M+23,048%	$2.35M—	——	$750K—	——
Retained earnings	-$150.65M-22.1%	-$123.42M—	——	-$49.23M—	——
Accumulated other comprehensive income (loss)	-$524K-973%	$60K—	——	$0—	——
Total stockholders' equity	$390.64M+423%	-$121.01M-99.5%	-$60.67M-25.1%	-$48.48M—	——
Total liabilities and stockholders' equity	$397.36M+160%	$152.62M—	——	$55.54M—	——
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	$289.4M+154%	$114M—	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	$389.61M+178%	$140.3M—	——	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	$267.4M+2,685%	$9.6M—	——	——	——
Available For Sale Securities Debt Securities Current	$222.39M+85.2%	$120.1M—	——	$0—	——
Other current assets	$602K+96.1%	$307K—	——	——	——
Investments - Amortized Cost Basis	$390.13M+178%	$140.24M—	——	——	——
Net Investment in Lease	$266K+158%	$103K—	——	$0—	——
Operating lease right-of-use assets	$266K+158%	$103K—	——	$0—	——
Operating Lease Right-of-Use Assets in Other Assets	$266K+158%	$103K—	——	$0—	——
Other Commercial Liabilities	$5.61M-19.7%	$6.98M—	——	$2.47M—	——
Accrued Liabilities, Current	$5.61M-19.7%	$6.98M—	——	$2.47M—	——
Other accrued liabilities	$39K-17.0%	$47K—	——	$0—	——
Total debt	——	$4K—	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1K0.0%	$1K—	——	$1K—	——
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——	——	——
Stockholders' Equity Note, Subscriptions Receivable	$1.23M—	$0—	——	——	——
Temporary Equity, Shares Subscribed but Unissued, Subscriptions Receivable	$0-100%	$1.85M-47.0%	$3.49M-9.3%	$3.85M—	——
Investments - Gross Unrealized Losses	$267.4M+2,685%	$9.6M—	——	——	——
Cumulative Cost Basis	$390.13M+178%	$140.24M—	——	——	——
Accrued bonuses	$563K-71.0%	$1.94M—	——	——	——
Professional service fees	$3.02M-30.3%	$4.34M—	——	——	——
Research and development	$2.02M+188%	$702K—	——	——	——
Total	$390.13M+178%	$140.24M—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	$0—	$0—	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	$0—	$0—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$100.73M+284%	$26.24M—	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$100.31M+282%	$26.25M—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10	$0—	$0—	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10	$0—	$0—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	$289.4M+154%	$114M—	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$289.3M+154%	$114.05M—	——	——	——
Common stock, par value (in dollars per share)	$0.000.0%	$0.00—	——	——	——
Common stock, shares authorized (in shares)	200M-25.2%	267.5M—	——	98.8M—	——
Common stock, shares issued (in shares)	37.3M+4,880%	749.8K—	——	——	——
Common Stock, Shares, Outstanding	37.3M+4,880%	749.8K—	——	——	——
Number of votes per share of common stock	1—	——	——	——	——
Accrued interest available-for-sale debt securities	$1.9M+111%	$900K—	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	$267.4M+2,685%	$9.6M—	——	——	——
Other contract costs	$0-100%	$3.39M—	——	——	——
Tax receivable within other current assets	$1.21M-3.3%	$1.26M—	——	——	——
Interest receivable on interest rate and cross currency swaps	$438K+919%	$43K—	——	——	——
Preferred stock, automatic conversion, conversion price multiplier	——	$1.2—	——	——	——
Preferred stock, automatic conversion, minimum public common stock offering proceeds	——	$100M—	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0.000.0%	$0.00—	——	——	——
Preferred Stock, Shares Authorized	25M—	0—	——	——	——
Preferred Stock, Shares Issued	0—	0—	——	——	——
Preferred Stock, Shares Outstanding	0—	0—	——	——	——
Prepaid Insurance	$759K+2,348%	$31K—	——	——	——
Prepaid research and development	$3.26M-41.9%	$5.61M—	——	——	——
Exercise price, percentage of fair market value at grant date, minimum	100%—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Veradermics 's total assets?: Veradermics (MANE) holds $397.4M in total assets.
How much cash does Veradermics have?: Veradermics holds $168.4M in cash and equivalents.
Can Veradermics cover its short-term obligations?: Its current ratio is 59.12 — current assets exceed current liabilities.
Where does Veradermics 's balance sheet data come from?: Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.